Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 38, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13046-019-1412-8
Keywords
Hepatocellular carcinoma; Molecular targeted therapy; Immunotherapy
Categories
Funding
- Regional science fund project of China natural science foundation [81660498]
- Youth talent fund project of China natural science foundation [81803007]
- Youth talent fund project of GuangXi natural science foundation [2016GXNSFBA380090, 2018GXNSFBA281030, 2018GXNSFBA281091]
- Guangxi Medical and Health Appropriate Technology Development and Application Project [S2017101, S2018062]
- Basic Ability Enhancement Program for Young and Middle-aged Teachers of Guangxi [2017KY0120]
- Guangxi Scholarship Fund of Guangxi Education Department
Ask authors/readers for more resources
Molecular targeted therapy for advanced hepatocellular carcinoma (HCC) has changed markedly. Although sorafenib was used in clinical practice as the first molecular targeted agent in 2007, the SHARPE and Asian-Pacific trials demonstrated that sorafenib only improved overall survival (OS) by approximately 3 months in patients with advanced HCC compared with placebo. Molecular targeted agents were developed during the 10-year period from 2007 to 2016, but every test of these agents from phase II or phase III clinical trial failed due to a low response rate and high toxicity. In the 2 years after, 2017 through 2018, four successful novel drugs emerged from clinical trials for clinical use. As recommended by updated Barcelona Clinical Liver cancer (BCLC) treatment algorithms, lenvatinib is now feasible as an alternative to sorafenib as a first-line treatment for advanced HCC. Regorafenib, cabozantinib, and ramucirumab are appropriate supplements for sorafenib as second-line treatment for patients with advanced HCC who are resistant, show progression or do not tolerate sorafenib. In addition, with promising outcomes in phase II trials, immune PD-1/PD-L1 checkpoint inhibitors nivolumab and pembrolizumab have been applied for HCC treatment. Despite phase III trials for nivolumab and pembrolizumab, the primary endpoints of improved OS were not statistically significant, immune PD-1/PD-L1 checkpoint therapy remains to be further investigated. This review summarizes the development and progression of molecular targeted and immune-based checkpoint therapies in HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available